Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
As Forte fails, who might yet improve the image of reverse mergers?
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
How long will the good times roll for medtech?
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Why some Spac deals are not all they’re cracked up to be
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
EQRX aims for biopharma Spac record
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
